Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS, Padley RJ.
Carducci MA, et al. Among authors: donehower r.
J Clin Oncol. 2002 Apr 15;20(8):2171-80. doi: 10.1200/JCO.2002.08.028.
J Clin Oncol. 2002.
PMID: 11956279
Clinical Trial.